表皮生长因子受体
受体
癌症研究
生长因子受体
酪氨酸激酶
生长因子受体抑制剂
受体酪氨酸激酶
胰岛素样生长因子1受体
ROR1型
靶向治疗
ERBB3型
生物
医学
癌症
血小板源性生长因子受体
生长因子
内科学
作者
Maurizio Scaltriti,José Baselga
标识
DOI:10.1158/1078-0432.ccr-05-1554
摘要
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase receptor that is frequently expressed in epithelial tumors. The EGFR was the first receptor to be proposed as a target for cancer therapy, and after 2 decades of intensive research, there are several anti-EGFR agents available in the clinic. Recent advances in our understanding in the mechanisms of receptor activation and function, discovery of primary and secondary EGFR somatic mutations, as well as a new generation of anti-EGFR agents provide new leads on the clinical targeting of this receptor and may serve as a model for strategies aimed at targeting other receptors.
科研通智能强力驱动
Strongly Powered by AbleSci AI